What are analysts' ratings for ARWR?
Equity research analysts covering Arrowhead Pharmaceuticals, Inc. (ARWR) maintain a strong consensus buy rating, supported by institutional enthusiasm for its proprietary RNA interference (RNAi) therapeutic discovery platform. Research reports emphasize the company's robust clinical pipeline targeting genetically validated diseases, alongside lucrative licensing agreements and partnerships with major global pharmaceutical corporations. Institutional sentiment reflects high confidence in Arrowhead's technological platform capabilities to deliver innovative treatments, offsetting short-term biotechnology sector volatility and capital burn considerations.
Related FAQs
Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, is based in Pasadena, California, United States.
ARWR stock represents the publicly traded equity shares of Arrowhead Pharmaceuticals, Inc., a prominent biotechnology enterprise listed on the NASDAQ global select market.
Evaluating Arrowhead Pharmaceuticals (ticker ARWR) as an equity investment requires analyzing its innovative RNA interference therapeutic pipeline, clinical trial milestones, and major pharmaceutical partnership agreements.
Wall Street equity research analysts maintain an overwhelmingly bullish consensus on Amazon (AMZN), with approximately 96% of covering analysts rating the stock as a Buy and a 12-month median price target hovering around $295 per share.
Arrowhead Pharmaceuticals, traded under the ticker ARWR, commands a market capitalization in the double-digit billions in U.S. dollars.
Armstrong ceiling tiles are manufactured using a diverse range of durable, acoustic-rated materials tailored for commercial and residential architectural applications.
Wall Street analysts view Pfizer Inc.
Determining if Arrowhead Pharmaceuticals represents a compelling long-term stock involves assessing its scientific leadership in gene silencing technologies and its ability to commercialize breakthrough RNAi therapeutics.
An analyst price target is a financial equity researcher's projected future price for a publicly traded stock over a specific time horizon, typically twelve months.
Astronics Corporation is a leading global supplier of advanced technologies, lighting, electrical power systems, and avionics structures for the aerospace, defense, and semiconductor industries.
Arrowhead Pharmaceuticals operates within strict bioethical and regulatory compliance standards established by international health authorities, institutional review boards, and government regulatory agencies for clinical drug development.
Cohen & Steers, Inc. is a prominent specialized global investment management firm recognized as an industry leader in real estate securities, real assets, and alternative income strategies.
Arrowhead Pharmaceuticals focuses on discovering and developing innovative therapeutics designed to treat genetically driven conditions by utilizing its proprietary targeted RNA interference platform.
The ticker symbol ARWR represents shares of Arrowhead Pharmaceuticals, Inc., a publicly traded biotechnology company listed on the Nasdaq stock exchange.
Evaluating the share price volatility of Eagers Automotive—traded on the Australian Securities Exchange under the ticker APE—reveals a moderate to high volatility profile characteristic of consumer discretionary retail and automotive dealership group...
Wall Street research analysts covering Arrowhead Pharmaceuticals, Inc. (ARWR) establish consensus 12-month average price targets centering around $96.92 per share.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a clinical-stage biopharmaceutical enterprise specializing in the development of novel therapies for central nervous system disorders.
Equity research analysts tracking Arrowhead Pharmaceuticals, Inc. formulate price predictions based on clinical pipeline milestones, RNA interference therapeutic platform advancements, and strategic pharmaceutical partnerships.